Brain volume loss linked to Alzheimer’s treatment may be caused by amyloid plaque removal A loss of brain volume associated with new immunotherapies for Alzheimer’s disease may be caused by the removal of amyloid…
Lecanemab effectively targets amyloid plaques in people with Down syndrome, study finds People with Down syndrome are likely to develop Alzheimer’s disease at a young age. Autopsy studies show that by age…
Amyloid immunotherapy for early Alzheimer’s: Promising but fraught with challenges In a recent perspective piece published in the Journal of the Alzheimer’s Association Alzheimer’s and dementiaresearchers from the United Kingdom…
Cambridge experts question efficacy and practicality of new amyloid immunotherapy drugs Cambridge researchers have raised doubts about whether new amyloid immunotherapy drugs will have the desired effect of significantly reducing the…
